Alexion Pharmaceuticals - M&A Summary, Ownership, and Business Overview

Life ScienceCompany

Alexion Pharmaceuticals M&A Summary

Alexion Pharmaceuticals has acquired 9 companies of its own, including 3 in the last 5 years. A total of 1 acquisition came from private equity firms.

Alexion Pharmaceuticals’ largest acquisition to date was in 2015, when it acquired Synageva BioPharma for $8.4B. Alexion Pharmaceuticals has acquired in 3 different US states, and 3 countries. The Company’s most targeted sectors include life science (89%) and healthcare services (12%).

Alexion Pharmaceuticals Ownership

Who owns Alexion Pharmaceuticals?

Alexion Pharmaceuticals is owned by AstraZeneca. It was acquired on December 12, 2020.

Alexion Pharmaceuticals Business Overview

Where is Alexion Pharmaceuticals headquartered?

Alexion Pharmaceuticals is headquartered in Boston, Connecticut.

What is Alexion Pharmaceuticals’ revenue?

Alexion Pharmaceuticals disclosed revenue of 6,070M USD for 2020 and 4,991M USD for 2019.

How many employees does Alexion Pharmaceuticals have?

Alexion Pharmaceuticals has 3,082 employees.

What sector is Alexion Pharmaceuticals in?

Alexion Pharmaceuticals is a life science company.

When was Alexion Pharmaceuticals founded?

Alexion Pharmaceuticals was founded in 1992.

M&A Summary

  • M&A Total Activity9
    • M&A Buy Activity9
  • Total Sectors Invested 2
  • Total Countries Invested 3
  • M&A Buy/Sell Connections 1
  • M&A Advisors 9

Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc.

121 Seaport Boulevard,
Boston, Connecticut 02210
United States,
(203) 272-2596
www.alexion.com

Alexion Pharmaceuticals is a biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Alexion Pharmaceuticals was formed in 1992 and is based in New Haven, Connecticut.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.4/yr) # 7 1 - 1 - - 9
vol $12.6B $12.6B
Sell (0.0/yr) # - - - - - - 0
  9

Most Recent M&A

Company Date Value Type
LogicBio Therapeutics, Inc. 2022-10-03 - Add-on Acquisition
Lexington, Massachusetts · www.logicbio.com
Portola Pharmaceuticals, Inc. 2020-05-05 - Add-on Acquisition
South San Francisco, California · www.portola.com
Achillion Pharmaceuticals, Inc. 2019-10-16 930M USD Add-on Acquisition
Blue Bell, Pennsylvania · www.achillion.com
Syntimmune 2018-09-26 1.2B USD Add-on Acquisition
Boston, Massachusetts · www.syntimmune.com
Wilson Therapeutics AB 2018-04-11 855M USD Add-on Acquisition
Stockholm, Sweden · www.wilsontherapeutics.com
Synageva BioPharma Corp. 2015-05-06 8.4B USD Add-on Acquisition
Lexington, Massachusetts · www.synageva.com
Enobia Pharma Corp. 2011-12-28 1.1B USD Add-on Acquisition
Montreal, Quebec · www.enobia.com
Taligen Therapeutics, Inc. 2011-01-31 111M USD Add-on Acquisition
Cambridge, Massachusetts · www.taligentherapeutics.com
Prolifaron, Inc. 2000-09-25 41M USD Add-on Acquisition
San Diego, California
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 8 (89%) 11.5B (91%) - -
Healthcare Services 1 (11%) 1.1B (9%) - -
Total 9 $12.6B - -

By Geo

State/Country Buy Value Sell Value
United States 7 10.7B - -
  Massachusetts 4 9.7B - -
  California 2 41M - -
  Pennsylvania 1 930M - -
Canada 1 1.1B - -
  Quebec 1 1.1B - -
Sweden 1 855M - -
Domestic 7 (78%) 10.7B (85%) - -
Cross-border 2 (22%) 1.9B (15%) - -
Total 9 $12.6B - -

Top M&A Advisors

Financial Deals
Lazard Ltd.
1
BofA Securities
1
J.P. Morgan Securities
1
Legal Deals
Ropes & Gray
2
Freshfields
1
Advokatfirman Cederquist KB
1

Deal Values

buy # Total
> $1B 3 $10.7B
$100M to $1B 3 $1.9B
< $100M 1 $41M
TOTAL $12.6B
Largest Synageva BioPharma Corp.
$8.4B (2015-05-06)

M&A Connections

Deals
Acquired from
Investor(s)
11%
1 (11%)

 Subscribe to unlock this and 202,424
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 194K M&A Transactions
  • 198K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.